Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 8/20 | 0.52 |
| ▸ | NOS3 | P29474 | 7/20 | 0.52 |
| ▸ | NOS1 | P29475 | 4/20 | 0.42 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.40 |
| ▸ | PRKCI | P41743 | 1/20 | 0.37 |
| ▸ | F12 | P00748 | 1/20 | 0.34 |
| ▸ | PLAU | P00749 | 1/20 | 0.34 |
| ▸ | NCF1 | P14598 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | DHFR | P00374 | 1/20 | 0.34 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.33 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6031149 | 0.83 | NOS2 (0.53) | NOS2NOS3NOS1TLR8CYP2E1 | |
| SCHEMBL26489048 | 0.80 | NOS2 (0.44) | NOS2NOS3NOS1CYP2E1CYP2C8 | |
| SCHEMBL357771 | 0.80 | NOS2 (0.64) | NOS2NOS3NOS1TLR8PRKCI | |
| SCHEMBL1433191 | 0.80 | NOS2 (0.41) | NOS2NOS3NOS1TLR8CYP2E1 | |
| SCHEMBL20001577 | 0.80 | NOS2 (0.56) | NOS2NOS3NOS1TLR8PRKCI | |
| SCHEMBL27900729 | 0.79 | TLR8 (0.47) | NOS2NOS3TLR8 | |
| SCHEMBL18066852 | 0.78 | NOS2 (0.47) | NOS2NOS3NOS1TLR8PRKCI | |
| SCHEMBL7841664 | 0.78 | NOS2 (0.39) | NOS2NOS3NOS1CYP2E1CYP2C8 | |
| SCHEMBL8134172 | 0.78 | NOS2 (0.47) | NOS2NOS3NOS1TLR8PRKCI | |
| SCHEMBL9189865 | 0.78 | NOS2 (0.39) | NOS2NOS3NOS1CYP2E1CYP2C8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024058617-A1 | ANTIVIRAL USE OF HETEROARYL DERIVATIVE COMPOUND | 일동제약(주) | 2024-03-21 | — | — | WO | disclosed |
| WO-2024019541-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | 일동제약(주) | 2024-01-25 | — | — | WO | disclosed |
| US-11600791-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2023-03-07 | — | — | US | disclosed |
| EP-3894416-B1 | FERROPORTIN INHIBITORS AND METHODS OF USE | GLOBAL BLOOD THERAPEUTICS INC (US) | 2022-11-09 | — | — | EP | disclosed |
| EP-3936512-A1 | PYRIDYL CARBENE PHOSPHORESCENT EMITTERS | Universal Display Corporation (US) | 2022-01-12 | — | — | EP | disclosed |
| CN-113387962-A | Pyrazolo [3,4-d ] pyrimidine-3-one derivative, pharmaceutical composition and application thereof | 上海迪诺医药科技有限公司 | 2021-09-14 | — | — | CN | disclosed |
| EP-3424935-B1 | IMIDAZOPYRAZINYL CARBENE PHOSPHORESCENT EMITTERS | UNIVERSAL DISPLAY CORP (US) | 2021-08-11 | — | — | EP | disclosed |
| US-20210050530-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2021-02-18 | — | — | US | disclosed |
| US-10873038-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2020-12-22 | — | — | US | disclosed |
| EP-3313397-B1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | MERCK SHARP & DOHME (US) | 2020-11-25 | — | — | EP | disclosed |
| US-20120228583-A1 | PYRIDYL CARBENE PHOSPHORESCENT EMITTERS | UNIVERSAL DISPLAY CORPORATION (US) | 2012-09-13 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| WO-2010059401-A2 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | IRM LLC (BM) | 2010-05-27 | — | — | WO | disclosed |
| US-20100029643-A1 | HETEROCYCLYC SULFONAMIDES HAVING EDG-1 ANTAGONISTIC ACTIVITY | ASTRAZENECA AB (SE) | 2010-02-04 | — | — | US | disclosed |
| CN-101611018-A | Heterocyclic sulfonamide with Edg-I antagonistic activity | ASTRAZENECA AB (SE) | 2009-12-23 | — | — | CN | disclosed |
| EP-2094670-A1 | HETEROCYCLYC SULFONAMIDES HAVING EDG-I ANTAGONISTIC ACTIVITY | AstraZeneca AB (SE) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008056150-A1 | HETEROCYCLYC SULFONAMIDES HAVING EDG-I ANTAGONISTIC ACTIVITY | ASTRAZENECA AB (SE) | 2008-05-15 | — | — | WO | disclosed |
| US-20060090270-A9 | Novel 6-alkoxy-2, 3-diaminopyridine couplers in which the amino radical in position 2 is a disubstituted amino radical, and use of these couplers for dyeing keratin fibres | VIDAL LAURENT | 2006-05-04 | — | — | US | disclosed |
| US-20050086747-A1 | Novel 6-alkoxy-2, 3-diaminopyridine couplers in which the amino radical in position 2 is a disubstituted amino radical, and use of these couplers for dyeing keratin fibres | L'OREAL S.A. (FR) | 2005-04-28 | — | — | US | disclosed |
| US-4931487-A | Chain extenders for polyurethanes | DOW CHEMICAL COMPANY | 1990-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | NOS2 887/4885NOS3 1368/4885NOS1 1487/4885 |
| US-20210050530-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | NUDC, NCL, NDC1 | NOS2 187/4885NOS3 777/4885NOS1 471/4885 |
| US-10873038-B2 | Organic electroluminescent materials and devices | NUDC, NCL, NDC1 | NOS2 187/4885NOS3 777/4885NOS1 471/4885 |
| US-20100029643-A1 | HETEROCYCLYC SULFONAMIDES HAVING EDG-1 ANTAGONISTIC ACTIVITY | EDF1, ERLIN1, ECE1 | NOS2 1380/4885NOS3 1565/4885NOS1 646/4885 |
| US-20120228583-A1 | PYRIDYL CARBENE PHOSPHORESCENT EMITTERS | PAICS, PIR, NUDC | NOS2 722/4885NOS3 1681/4885NOS1 1578/4885 |
| US-11600791-B2 | Organic electroluminescent materials and devices | NUDC, NCL, NDC1 | NOS2 187/4885NOS3 777/4885NOS1 471/4885 |
| US-20060090270-A9 | Novel 6-alkoxy-2, 3-diaminopyridine couplers in which the amino radical in position 2 is a disubstituted amino radical, and use of these couplers for dyeing keratin fibres | KRT18, QDPR, PYCR1 | NOS2 1952/4885NOS3 1961/4885NOS1 2671/4885 |
| US-20050086747-A1 | Novel 6-alkoxy-2, 3-diaminopyridine couplers in which the amino radical in position 2 is a disubstituted amino radical, and use of these couplers for dyeing keratin fibres | KRT18, QDPR, PYCR1 | NOS2 1952/4885NOS3 1961/4885NOS1 2671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.